MEI Pharma (NASDAQ:MEIP) Earns Buy Rating from Analysts at initiated coverage on shares of MEI Pharma (NASDAQ:MEIPFree Report) in a research note released on Wednesday. The brokerage issued a buy rating on the stock.

Several other equities analysts have also weighed in on MEIP. Stifel Nicolaus reaffirmed a hold rating and set a $7.00 target price on shares of MEI Pharma in a report on Friday, April 12th. TheStreet downgraded shares of MEI Pharma from a c- rating to a d+ rating in a research report on Thursday, February 1st.

Check Out Our Latest Report on MEI Pharma

MEI Pharma Price Performance

NASDAQ:MEIP opened at $3.15 on Wednesday. The business has a fifty day simple moving average of $3.50 and a two-hundred day simple moving average of $4.86. The company has a market capitalization of $20.98 million, a P/E ratio of 0.80 and a beta of 0.82. MEI Pharma has a 1 year low of $2.87 and a 1 year high of $7.97.

MEI Pharma (NASDAQ:MEIPGet Free Report) last issued its earnings results on Tuesday, February 13th. The company reported ($1.66) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.46) by ($0.20). MEI Pharma had a return on equity of 48.32% and a net margin of 39.06%. As a group, analysts anticipate that MEI Pharma will post 3.22 earnings per share for the current year.

Institutional Trading of MEI Pharma

A hedge fund recently bought a new stake in MEI Pharma stock. National Bank of Canada FI purchased a new stake in shares of MEI Pharma, Inc. (NASDAQ:MEIPFree Report) in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm purchased 6,000 shares of the company’s stock, valued at approximately $36,000. National Bank of Canada FI owned about 0.09% of MEI Pharma as of its most recent filing with the Securities & Exchange Commission. 52.38% of the stock is owned by institutional investors.

MEI Pharma Company Profile

(Get Free Report)

MEI Pharma, Inc, a clinical-stage pharmaceutical company, focuses on the development and commercialization of various therapies for the treatment of cancer. The company develops Zandelisib, an oral phosphatidylinositol 3-kinase delta inhibitor for the treatment of patients with relapsed/refractory follicular lymphoma; and Voruciclib, an oral cyclin-dependent kinase 9 inhibitor, which is in Phase I clinical trial for acute myeloid leukemia and B-cell malignancies.

Featured Stories

Receive News & Ratings for MEI Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MEI Pharma and related companies with's FREE daily email newsletter.